Azur Pharma acquired product rights to Gastrocrom
Azur Pharma Limited (“Azur Pharma”) today announced that it has acquired the U.S. rights to Gastrocrom® (cromolyn sodium, usp Oral Concentrate) from UCB Pharma, Inc (“UCB”). Gastrocrom® is indicated in the management of patients suffering from mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems. Annual sales of Gastrocrom® amount to approximately US$5 million.
“I am pleased to announce our first product acquisition, Gastrocrom®, a mature and stable prescription product indicated for a rare and often chronic disorder. This acquisition is an important first step as we seek to execute on our mission of creating a U.S. pharmaceutical business focused on developing and marketing products in specialist therapeutic areas.” commented Mr. Seamus Mulligan, Azur Pharma’s Chairman and Chief Executive Officer.